Lexicon Pharmaceuticals (NASDAQ:LXRX) was downgraded by ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued on Friday.
LXRX has been the subject of a number of other reports. Zacks Investment Research downgraded shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday. BidaskClub raised shares of Lexicon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, January 20th. Finally, Wedbush reissued an “outperform” rating on shares of Lexicon Pharmaceuticals in a research report on Thursday, October 5th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $28.50.
Lexicon Pharmaceuticals (NASDAQ LXRX) traded down $0.13 during trading on Friday, hitting $9.77. 576,992 shares of the stock were exchanged, compared to its average volume of 548,392. Lexicon Pharmaceuticals has a 1 year low of $8.07 and a 1 year high of $18.00. The company has a quick ratio of 1.65, a current ratio of 1.66 and a debt-to-equity ratio of 1.09.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.07. Lexicon Pharmaceuticals had a negative net margin of 165.69% and a negative return on equity of 111.68%. The firm had revenue of $26.94 million during the quarter, compared to the consensus estimate of $27.97 million. During the same period in the prior year, the firm earned ($0.35) EPS. The company’s revenue was down 2.8% compared to the same quarter last year. equities analysts expect that Lexicon Pharmaceuticals will post -1.38 EPS for the current fiscal year.
In other Lexicon Pharmaceuticals news, Director Public Equities L.P. Invus purchased 180,727 shares of the company’s stock in a transaction that occurred on Friday, November 17th. The shares were bought at an average cost of $10.11 per share, for a total transaction of $1,827,149.97. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, CEO Lonnel Coats purchased 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 15th. The shares were acquired at an average price of $9.91 per share, for a total transaction of $99,100.00. Following the completion of the purchase, the chief executive officer now directly owns 42,985 shares in the company, valued at approximately $425,981.35. The disclosure for this purchase can be found here. Insiders have purchased a total of 914,353 shares of company stock worth $8,916,253 over the last 90 days. 5.77% of the stock is currently owned by corporate insiders.
Several hedge funds have recently made changes to their positions in LXRX. Schwab Charles Investment Management Inc. lifted its stake in shares of Lexicon Pharmaceuticals by 0.9% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 193,318 shares of the biopharmaceutical company’s stock valued at $3,181,000 after buying an additional 1,633 shares in the last quarter. Legal & General Group Plc lifted its stake in shares of Lexicon Pharmaceuticals by 2.6% during the 2nd quarter. Legal & General Group Plc now owns 18,570 shares of the biopharmaceutical company’s stock valued at $305,000 after buying an additional 465 shares in the last quarter. Teachers Advisors LLC lifted its stake in shares of Lexicon Pharmaceuticals by 8.5% during the 2nd quarter. Teachers Advisors LLC now owns 77,189 shares of the biopharmaceutical company’s stock valued at $1,270,000 after buying an additional 6,077 shares in the last quarter. Ameriprise Financial Inc. purchased a new stake in shares of Lexicon Pharmaceuticals during the 2nd quarter valued at approximately $1,261,000. Finally, Nationwide Fund Advisors lifted its stake in shares of Lexicon Pharmaceuticals by 4.5% during the 2nd quarter. Nationwide Fund Advisors now owns 76,747 shares of the biopharmaceutical company’s stock valued at $1,262,000 after buying an additional 3,289 shares in the last quarter.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/04/valuengine-downgrades-lexicon-pharmaceuticals-lxrx-to-strong-sell.html.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.